The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 10206 malaria professionals are enjoying the free benefits of MalariaWorld today

Primaquine–quinoxaline

Primaquine–quinoxaline 1,4-di-N-oxide hybrids with action on the exo-erythrocytic forms of Plasmodium induce their effect by the production of reactive oxygen species

June 24, 2019 - 15:48 -- Open Access
Tags: 
Author(s): 
Leonardo Bonilla-Ramírez, Silvia Galiano, Miguel Quiliano, Ignacio Aldana and Adriana Pabón
Reference: 
Malaria Journal 2019 18:201,19 June 2019

The challenge in anti-malarial chemotherapy is based on the emergence of resistance to drugs and the search for medicines against all stages of the life cycle of Plasmodium spp. as a therapeutic target. Nowadays, many molecules with anti-malarial activity are reported. However, few studies about the cellular and molecular mechanisms to understand their mode of action have been explored. Recently, new primaquine-based hybrids as new molecules with potential multi-acting anti-malarial activity were reported and two hybrids of primaquine linked to quinoxaline 1,4-di-N-oxide (PQ–QdNO) were identified as the most active against erythrocytic, exoerythrocytic and sporogonic stages.

Medical Treatment: 
Subscribe to RSS - Primaquine–quinoxaline